Report - LifeSciences BC

More documents

Recommendations

Info

DCRTSubmissionof FindingsChart One: Submission Review ProcessDRUG BENEFIT COUNCILBroad membership with relevant decision making expertise- transparent appointment process- robust conflict of interest terms for each member for each submission,including bias- proper governanceEstablishes Drug Review Resource Committee (DRRC)Reviews & recommends acceptance or rejection of DCRT findings to PSDDrug Review Resource Committee(Sub-committee of the DBC)Maintains open registry of experts; therapeutic indications, economics, clinical practiceMembership: 4 members from DBC, 1 year rotation plus PSD’s DIDSelect 5 experts for each drug file to sit on a Drug Coverage Review TeamDCRT DCRT DCRT DCRT DCRTDrug Coverage Review Teams (DCRT)Mandate:Review file for recommendation- critically review and appraise relevant literature- review manufacturers submission- review CDR file (if available)If required, gathers inputs from other sources, experts or stakeholdersMembership structure from DRRC Registry: Chair plus 4 team membersReports to the Drug Benefit CouncilDBCRecommendation toMinistry of HealthPSDDrugIntelligenceDirector(DID)Drug FileAllocationTHE REPORT OF PHARMACEUTICAL POLICY RECOMMENDATIONS FOR THE MINISTRY OF HEALTH 13APRIL, 2008
Recommendations for an Improved Listing ProcessRecommendation One:Priority attention should be focused ondevelopment of an enhanced FormularyManagement System together withimproved stakeholder engagement andappeal mechanisms. This work shouldbe led by the Pharmaceutical ServicesDivision and include meaningfulengagement with stakeholders, includingpatients, healthcare professionals,disease specialists, research leaders andindustry.Recommendation Two:The Ministry of Health should act toestablish new target review/listingdecision guidelines with the goal ofsubstantially improving BritishColumbia's performance on time-tolistingdecisions. Progress on this frontmust be publicly reported andconsistently benchmarked against theperformance of other jurisdictions.Recommendation Three:The Drug Benefit Committee should bereconstituted as the “Drug BenefitCouncil” to more appropriately reflectthe arms length role it is expected tocarry out in the review processesapplicable to consideration of newtherapies.Recommendation Four:The Ministry of Health should establisha new Drug Review ResourceCommittee to carry out the drugsubmission review role currentlyperformed by the TherapeuticsInitiative. This new DRRC should alsoprovide for a registry of experts thatwill substantially widen the array ofexpertise available to offer advice andrecommendations on the therapeuticvalue and cost-effectiveness of newdrug therapies.Recommendation Five:The membership of the DBC shouldbe modified to include the participationof at least three public membersselected through a process external tothe PSD. Government may also wishto consider ensuring that at least onemember of the DBC has broadeconomic expertise to supplement theexisting expertise that is focused morenarrowly on health economics.Recommendation Six:No members of the TherapeuticsInitiative or, in the alternative, noparticipant in a Drug Coverage ReviewTeam should participate as members inthe work of the Drug Benefit Council.THE REPORT OF PHARMACEUTICAL POLICY RECOMMENDATIONS FOR THE MINISTRY OF HEALTH 14 APRIL, 2008
Page 1 and 2: REPORT OF THE PHARMACEUTICAL TASK F
Page 3 and 4: Table of ContentsTask Force Mandate
Page 5 and 6: In addition to the submissions from
Page 7 and 8: pharmaceutical coverage programs ha
Page 9 and 10: these factors may potentially resul
Page 11 and 12: 14formulary”; andBC should benchm
Page 13 and 14: meaningful engagement with stakehol
Page 15: contributions from Drs. Ken Bassett
Page 19 and 20: Generic Drugs - Call for aFundament
Page 21 and 22: The Task Force also considered thea
Page 23 and 24: was understood that the cost of the
Page 25 and 26: The Task Force believes this is an
Page 27 and 28: participation in decision making, t
Page 29 and 30: Recommendation Twelve:Subject to Re
Page 31 and 32: Recommendation Eight: To increase t
Page 33 and 34: THE REPORT OF PHARMACEUTICAL POLICY

Report - LifeSciences BC

Create successful ePaper yourself

Delete template?

Save as template?